###begin article-title 0
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
Evaluation of MMP1 and MMP3 gene polymorphisms in exfoliation syndrome and exfoliation glaucoma
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
To investigate possible genetic associations of matrix metalloproteinase-1 (MMP1) and MMP3 gene polymorphisms with exfoliation syndrome (XFS) with (XFS/+G) and without (XFS/-G) glaucoma in a cohort of Greek patients.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
A total of 182 unrelated Greek patients with XFS, including 92 patients with XFS/+G, and 214 unrelated age- and gender-matched controls were enrolled in the study. MMP1 -1607 1G/2G () and MMP3 -1171 5A/6A () polymorphisms were determined using standard PCR/restriction fragment length polymorphism methods. Differences in allele and genotype distributions were analyzed using logistic regression.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
The distribution of genotypes and alleles in MMP1 and MMP3 polymorphisms was not significantly different between cases with exfoliation syndrome, with or without glaucoma, and controls. However, the allele contrast for the MMP1 variant showed a trend for a significant association with XFS/-G (Odds Ratio=1.47 [1.03-2.10]), since after correction for multiple comparisons, this association was no longer statistically significant.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Our study provided some evidence of a possible role of the MMP1 variant in the development of exfoliation syndrome in Greek patients.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
Exfoliation syndrome (XFS) is an age-related generalized disorder of the extracellular matrix associated with excessive synthesis and progressive deposition of a fibrillar material in the ocular tissues as well as in the skin and connective tissue of various visceral organs [1]. It is characterized by small whitish deposits of fibrillar-granular material in the anterior segment of the eye. Its ocular manifestations involve all the structures of the anterior segment as well as the conjunctiva and the orbital tissues [2]. An increased number of associations of XFS with specific systemic disorders [1] has been reported.
###end p 10
###begin p 11
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Raised intraocular pressure develops in a significant number of patients with exfoliation syndrome. Exfoliation glaucoma (XFS/+G) is a common sight-threatening disease that develops as a consequence of exfoliation syndrome. There are important differences in the clinical appearance, course, and prognosis of exfoliative glaucoma versus primary open-angle glaucoma. On clinical, biochemical, and cellular levels, XFS/+G is a distinct entity with an intriguing mechanism of development and numerous systemic manifestations that require further elucidation [3].
###end p 11
###begin p 12
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 618 619 618 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 1032 1033 1032 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
Extracellular matrix turnover is mediated by matrix metalloproteinases (MMPs), a large family of endopeptidases with variable substrate spectra [4]. The activity of these enzymes is regulated in part by specific endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Complex changes in the local MMP-TIMP are possible candidates to be involved in the abnormal extracellular matrix metabolism characteristic of XFS and XFS/+G. Increased biosynthesis of MMPs in eyes with XFS has been reported, and this may serve to degrade the abnormal fibrillar matrix components in the anterior segment tissues [5]. However, the increased levels of MMPs do not seem to be able to overcome the overproduction and accumulation of exfoliative material [5]. Growing evidence indicates that spontaneous sequence variations in the promoters of MMPs may influence critical steps in the binding of transcription factors or overall transcriptional efficiency, which results in differential expression of MMPs in different individuals [6].
###end p 12
###begin p 13
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
An insertion (2G)/deletion (1G) polymorphism () of MMP1 (OMIM , chr.11q22-q23) within the promoter region at position -1607 bp influences the transcription of this MMP1 gene; the 2G promoter processes greater transcriptional activity than the 1G promoter [7,8].
###end p 13
###begin p 14
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 430 434 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 439 443 439 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
There is also a single adenine insertion (6A) or deletion (5A) polymorphism () at position -1171 bp of the MMP3 (OMIM , chr.11q23) promoter that influences MMP3 expression by changing the affinity of the repressor binding site, with the 6A allele sequence having a stronger recognition for the repressor binding site. This leads to enhanced transcriptional levels of MMP3 in the presence of the 5A allele [6,9]. In addition, both MMP1 and MMP3 are known to be adjacently localized in chromosome 11q22.3, and these two loci are in linkage disequilibrium and considered to act in cooperation [10].
###end p 14
###begin p 15
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
Our study was designed to investigate whether the insertion/deletion polymorphisms of the MMP1 and MMP3 promoters have any correlation with the development of XFS, and XFS/+G in particular. To our knowledge, this is the first study that has evaluated the association between MMP1 and MMP3 polymorphisms and XFS and XFS/+G.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and control subjects
###end title 17
###begin p 18
###xml 744 751 744 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 709 717 <span type="species:ncbi:9606">patients</span>
This association study included 182 patients with unilateral or bilateral XFS, 92 of which had unilateral or bilateral exfoliation glaucoma (XFS/+G), 90 without glaucoma (XFS/-G), and 214 age- and gender-matched control subjects. All subjects were recruited from the Ophthalmologic Department of the University Hospital of Larissa (a tertiary referral center in central Greece that covers a population of almost one million inhabitants). The study was approved by the local ethics committee and carried out according to the Declaration of Helsinki. All subjects were of Greek nationality from the same geographic region and gave informed consent before entering the study. The age and sex distribution of the patients and controls are shown in Table 1.
###end p 18
###begin title 19
Clinical characteristics of study populations.
###end title 19
###begin p 20
In the table, XFS refers to exfoliation syndrome, XFS/+G refers to exfoliation syndrome with glaucoma, and XFS/-G refers to exfoliation syndrome without glaucoma.
###end p 20
###begin p 21
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 88 96 <span type="species:ncbi:9606">Patients</span>
All subjects underwent detailed ophthalmic examination by the same investigator (P.M.). Patients or controls with any type of malignancy, autoimmune disease, ocular disease, history of cardiovascular disease, neurologic disease, obstructive pulmonary disease, diabetes mellitus, hepatitis, or allergies were not included in the study because these conditions have been associated with abnormal expression of MMPs or their inhibitors [11].
###end p 21
###begin p 22
In a detailed ophthalmologic examination, the anterior and posterior segments of all cases were evaluated, and intraocular pressures (IOPs) were measured with Goldmann applanation tonometry, manufactured by Haag-Streit (Koeniz-Berne Switzerland). The corneal endothelium, iris, iris margins, and the anterior lens surface were evaluated for exfoliative material before and after dilation. To evaluate the angle for exfoliative material and increased pigmentation, gonioprisms were used.
###end p 22
###begin p 23
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 708 716 <span type="species:ncbi:9606">patients</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
Patients were classified as having unilateral or bilateral XFS by the presence of characteristic fibrillar-exfoliate material on the anterior lens capsule or pupillary margin and by an open anterior chamber angle. Unilateral or bilateral XFS/+G was manifested if patients had XFS as well as an IOP greater than 22 mmHg in each eye, typical glaucomatous optic nerve changes (notching, thinner neuroretinal rim, and increased cup-to-disc ratio), and the presence of visual field defects, as determined by a Humphrey visual field analyzer, (full threshold program 24-2; Carl Zeiss Inc., Dublin, CA), consistent with the glaucomatous cupping in at least one eye. The mean IOP at diagnosis was 17+/-4 mmHg in the patients with XFS and 35.0+/-13.0 mm Hg in the patients with XFS/+G.
###end p 23
###begin p 24
Control subjects had no evidence of exfoliative material at the anterior lens capsule or pupillary margin. In addition the IOP in control subjects was less than 22 mm Hg; control subjects had normal visual fields, an open anterior chamber angle, no evidence of glaucomatous changes in the optic disc, and no history of glaucoma or ocular hypertension in first-degree relatives.
###end p 24
###begin title 25
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
MMP1 and MMP3 polymorphisms
###end title 25
###begin p 26
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1 </italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> MMP3</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 325 329 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 360 367 360 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 427 428 427 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 467 468 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 482 483 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 506 507 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 510 514 510 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 565 566 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 621 622 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 731 735 726 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 740 744 735 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 910 914 905 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 934 938 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
Genomic DNA was extracted from peripheral blood leukocytes using a commercially available DNA extraction kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. Based on the sequences of MMP1 and MMP3 available from GenBank and using  software, appropriate primers were designed for MMP1 (1G/2G, -1607) and MMP3 (5A/6A, -1171) polymorphisms (Table 2). Thermal cycling conditions were as follows: 15 min at 95 oC, followed by 35 cycles of 30 s at 95 oC, 30 s at 56 oC (MMP1) or 30 s at 65 oC (MMP3), 30 s at 72 oC, and with a final extension at 72 oC for 5 min. PCR products were digested for 16 h at 37 oC in a 24-mul reaction containing 2 mul AluI and 2 mul TauthIII restriction enzymes for the determination of MMP1 and MMP3 genotypes, respectively. The digested products were subjected to gel electrophoresis and were visualized by ethidium bromide staining. The sizes of PCR products for MMP1 (1G/2G, -1607) and MMP3 (5A/6A, -1171) were 269 and 129 bp, respectively.
###end p 26
###begin title 27
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
Primer sequences for MMP1 (1G/2G, -1607) and MMP3 (5A/6A, -1171) polymorphisms.
###end title 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
###xml 38 40 38 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 450 451 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
The Hardy-Weinberg (H-W) equilibrium [12] was assessed by means of an exact H-W test, implemented in the  version 3.4 program. Power was calculated using the  Power Calculator for Genetic Studies (Center for Statistical Genetics, University of Michigan, Ann Arbor, MI). Continuous variables were compared (XFS total, XFS/+G, or XFS/-G versus controls) using the nonparametric Mann-Whitney U test, and categorical variables were compared using the chi2 test. Differences in allele and genotype distributions were analyzed using logistic regression. The odds ratio (OR) and 95% confidence interval (CI) were used as a measure of strength of association between polymorphisms and disease. In the logistic regression, the disease status (patients versus controls) was used as a dichotomous outcome, while allele or genotype was used as a predictor. We additionally controlled for potential confounders, such as age and gender. Later analyses were carried out using SPSS ver. 12.0 (SPSS, Chicago, IL). Control for multiple comparisons was performed using  correction for two polymorphisms. The level of significance (p) was equal to 0.025 (0.05/2=0.025).
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 243 250 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 516 520 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
Patients and controls were in Hardy-Weinberg equilibrium (p>0.05 for all groups). Differences in mean age and sex distribution between all patients and controls were not significant (p>0.05). Distribution of genotypes and alleles are shown in Table 3. In both polymorphisms (MMP1 and MMP3), the genotype distribution of the XFS total group was not significantly different from controls (p=0.19 and p=0.99). Also, the genotype distributions of XFS/+G and XFS/-G groups were not significantly different from controls (MMP1 p=0.10 and 0.70, respectively, and MMP3 p=0.94 and 0.48, respectively).
###end p 31
###begin title 32
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
Genotype and allele distribution frequencies of the MMP1 -1607 polymorphism and the MMP3 -1171 polymorphism.
###end title 32
###begin p 33
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
Genotype and allele distribution frequencies of the MMP1 -1607 polymorphism and the MMP3 -1171 polymorphism in the exfoliation syndrome (XFS Total), exfoliation syndrome with glaucoma (XFS/+G), exfoliation glaucoma without glaucoma (XFS/-G and control groups. The p-values for comparing each diseased group with the controls are also shown.
###end p 33
###begin p 34
###xml 194 201 194 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 606 610 606 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
The results of the influence of genotypes on disease susceptibility based on carrier status of risk allele and considering the allele contrast and the dominant and recessive models are shown in Table 4. The allele contrast for the MMP1 variant showed a trend for a significant association for XFS/-G (1.47 [1.03-2.10]; p=0.04). This association is considered nonsignificant after correction for multiple comparisons (level of significant <0.025). However, the dominant and recessive models showed that MMP1 was not associated with XFS total (OR=1.51 [0.87-2.46] and OR=0.73 [0.46-1.13], respectively). The MMP3 variant was not associated with XFS total for the allele contrast and the dominant and recessive models (OR=0.90 [0.68-1.19]; OR=1.09 [0.68n-1.65]; and OR=1.03 [0.66-1.54], respectively). The subgroups XFS/+G and XFS/-G produced similar results to the XFS total for both variants.
###end p 34
###begin title 35
Influence of genotypes on disease susceptibility based on carrier status of risk allele considering dominant or recessive model.
###end title 35
###begin p 36
The asterisk indicates that OR was adjusted for age and gender.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
XFS is a complex disorder with both genetic and nongenetic factors involved in its development and progression. Among nongenetic factors, ultraviolet light, autoimmunity, slow virus infection, and trauma have been suggested as contributing factors to XFS [13].
###end p 38
###begin p 39
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
Exfoliation syndrome is often clustered in families, so it has been proposed that genetic factors play an important role in its cause [14]. In an Icelandic twin study, five of eight monozygotic twins with exfoliation were concordant for XFS [15], as was the case in another small case study of monozygotic twins [14]. Segregation analyses conducted on the Finnish population clearly showed heredity to be a primary contributor to XFS susceptibility [14], and recently the susceptible loci were proposed to be 18q12.1-21.33, 2q, 17p, and 19q.9 [16].
###end p 39
###begin p 40
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOX1</italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 515 518 515 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GST</italic>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTT1</italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTP1</italic>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 594 604 590 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TNF&#945;)</italic>
###xml 644 646 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 647 649 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
In addition, genetic association studies have been conducted to investigate the association between genetic polymorphisms and XFS with or without glaucoma. Recent studies showed that lysil oxidase-like 1 (LOX1) gene polymorphisms are highly associated with exfoliation phenotype [17-20]. Replication studies in other populations have confirmed genetic susceptibility of LOXL1 polymorphisms to XFS [17,21,22], demonstrating that LOXL1 is a major gene associated with XFS. Polymorphisms in glutathione S-transferase (GST) genes (GSTM1, GSTT1, GSTP1) [23] and the tumor necrosis factor-alpha gene (TNFalpha) -308 G/A have also been tested in XFS [24,25].
###end p 40
###begin p 41
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
MMPs and their inhibitors are shown to play an important role in the development of an abnormal extracellular matrix characteristic of XFS/XFS/+G [2,26]. Increased biosynthesis of MMPs has been found in XFS, which may limit the progression of XFS by degrading the abnormal fibrillar matrix components in the anterior segment tissues; however, it was also suggested the MMPs may have a role in promoting exfoliation [5]. MMP1 (1G/2G, -1607) and MMP3 (5A/6A, -1171) functional polymorphisms have been studied in various diseases and in several populations [6]. They have been associated, among others, with increased risk for colorectal cancer [10], carotid artery disease [27], acute myocardial infarction [28], and idiopathic dilated cardiomyopathy [29].
###end p 41
###begin p 42
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
In the present study, we determined the genotypes of two functional polymorphisms, MMP1 (1G/2G, -1607) and MMP3 (5A/6A, -1171), in healthy individuals and in patients with XFS and XFS/+G, and for the allele contrast we found a trend for association only between the MMP1 variant and XFS without glaucoma.
###end p 42
###begin p 43
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 690 698 <span type="species:ncbi:9606">patients</span>
We should underscore that the sample size in our study was small, and thus the power of detecting significant results was limited (almost 20%). However, candidate-gene association studies have the tendency to lack the power to detect a statistically significant association. For example, in order to achieve a power >80% to identify a modest genetic effect (odds ratio 1.2) of a polymorphism present in 10% of individuals, a sample size of 10,000 subjects or more would be needed [30,31]. Therefore, the sample sizes required to predict association have to be far beyond what is currently available, and no single institution or entity alone would be able to provide a reasonable number of patients. However, a future meta-analysis of multiple studies clearly has a role in offering an analysis with the potential for higher power [32]. Future collaborative studies may allow the pooling of data, providing more power to detect significant associations. Furthermore, consortia performing gene-candidate or genome-wide association studies will be able to replicate the validity of the present findings [33].
###end p 43
###begin p 44
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
Nevertheless, the present study fulfills the minimum requirements for the association study to be informative [32]. These include population-based matched controls, good scientific rationale, presence of H-W equilibrium in genotypes, and a similar ethnic background. In parallel, our study has all the limitations that are applicable to genetic association studies [34]. Because our hospital is the only tertiary institution covering a rural and urban region with nearly 1 million inhabitants, patients included in this study are population-based XFS patients. For this reason, more severe patients are usually referred to our hospital, and we cannot exclude the possibility that a selection bias may have occurred.
###end p 44
###begin p 45
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
In summary, our study provided some evidence of a possible significant role of the MMP1 variant in the development of exfoliation syndrome in Greek patients. However, as we cannot exclude the possibility that our findings were due to random events or type 1 error, further studies using large cohorts of patients are needed to explore the possible genetic involvement of the above polymorphisms in the exfoliation syndrome.
###end p 45
###begin title 46
References
###end title 46
###begin article-title 47
Ocular and systemic pseudoexfoliation syndrome.
###end article-title 47
###begin article-title 48
Exfoliation (pseudoexfoliation) syndrome: toward a new understanding. Proceedings of the First International Think Tank.
###end article-title 48
###begin article-title 49
Current concepts in the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma.
###end article-title 49
###begin article-title 50
Matrix metalloproteinases.
###end article-title 50
###begin article-title 51
Matrix metalloproteinases and their inhibitors in exfoliation syndrome.
###end article-title 51
###begin article-title 52
Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.
###end article-title 52
###begin article-title 53
The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function.
###end article-title 53
###begin article-title 54
A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa.
###end article-title 54
###begin article-title 55
###xml 91 96 <span type="species:ncbi:9606">human</span>
Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression.
###end article-title 55
###begin article-title 56
Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer.
###end article-title 56
###begin article-title 57
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma.
###end article-title 57
###begin article-title 58
Low RLS prevalence and awareness in central Greece: an epidemiological survey.
###end article-title 58
###begin article-title 59
Exfoliation syndrome: frequency, gender distribution and association with climatically induced alterations of the cornea and conjunctiva.
###end article-title 59
###begin article-title 60
Exfoliation syndrome: prevalence and inheritance in a subisolate of the Finnish population.
###end article-title 60
###begin article-title 61
Chronic open-angle glaucoma and associated ophthalmic findings in monozygotic twins and their spouses in Iceland.
###end article-title 61
###begin article-title 62
Genome-wide scan of exfoliation syndrome.
###end article-title 62
###begin article-title 63
Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma.
###end article-title 63
###begin article-title 64
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Association of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma.
###end article-title 64
###begin article-title 65
Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese.
###end article-title 65
###begin article-title 66
Genetics of pseudoexfoliation syndrome.
###end article-title 66
###begin article-title 67
###xml 50 58 <span type="species:ncbi:9606">Patients</span>
Lysyl Oxidase-like 1 Gene Polymorphisms in German Patients With Normal Tension Glaucoma, Pigmentary Glaucoma and Exfoliation Glaucoma.
###end article-title 67
###begin article-title 68
Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India.
###end article-title 68
###begin article-title 69
Is GST gene polymorphism a risk factor in developing exfoliation syndrome?
###end article-title 69
###begin article-title 70
Tumor necrosis factor alpha-308 gene polymorphism and pseudoexfoliation glaucoma.
###end article-title 70
###begin article-title 71
###xml 86 94 <span type="species:ncbi:9606">patients</span>
TNF-alpha -308 G>A and -238 G>A polymorphisms are not major risk factors in Caucasian patients with exfoliation glaucoma.
###end article-title 71
###begin article-title 72
Exfoliation syndrome.
###end article-title 72
###begin article-title 73
Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis.
###end article-title 73
###begin article-title 74
Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction.
###end article-title 74
###begin article-title 75
Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population.
###end article-title 75
###begin article-title 76
Trends in meta-analysis of genetic association studies.
###end article-title 76
###begin article-title 77
Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches.
###end article-title 77
###begin article-title 78
Genomic convergence of genome-wide investigations for complex traits.
###end article-title 78
###begin article-title 79
Genome-wide association studies: hypothesis-"free" or "engaged"?
###end article-title 79
###begin article-title 80
Association study designs for complex diseases.
###end article-title 80

